21Feb 2017

ROLE OF NANOTECHNOLOGY IN EPIRUBICIN FOR BREAST CANCER THERAPY IN TAIF CITY

  • Department of Pharmacy, clinical Pharmacy, Taif University, Saudi Arabia.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: According to Breast Cancer Screening Programs in 26 Countries, 19.0% of females have breast cancer. The aim of our study is assessing the role of nanotechnology in breast cancer therapy. Epirubicin drug was selected as an example of the pharmaceutical nanosystem. Method: A cross sectional study was conducted among 300 women in Taif city and the data were collected using a self-administered questionnaire. The questionnaire determines the knowledge of risk factors and the disease stages (breast cancer). The patients also interviewed to determine the duration, the response and the feeling of any harmful symptoms after using of Epirubicin in the therapy. The answers were scored; frequencies and percentages were used for describing data. Chi-square test and a P value of (0.05) were used to determine the significant association between the participants' variables. Results: Most patients respondents were between 21 to above 70 years old. About 28.1% breast cancer patients discover the disease by the chance, while 46.9% by self-examination. 43.75% of breast cancer patients use Epirubicin drug. The effectiveness of therapy takes about 3 -9 months. 15.6% only have a serious common side effect and 18.7% have any side effect. Therefore the number of patients who accepted the therapy by Epirubicin was 78.6% Conclusion: Participants had poor knowledge about the disease and management. Using Epirubicin had a good attitude in managing time and compliance of the disease. The nanoparticle system presented in Epirubicin drug considers the solving of most common patient incompliance.

  1. Akashi, K. &Weissman, L. in Developmental Biology ofHematopoiesis (Oxford Univ. Press, New York,2001).
  2. Peter C. Nowel. Perspectives in Cancer Research Mechanisms ofTumor
  3. CANCER RESEARCH 46, 203-207, May1986
  4. Cancer Incidence Report Saudi Arabia2010
  5. International cancer screening network(ICSN)
  6. Subramaniam, T.E. Hefferan, K. Tau, D. Peus, M. Pittelkow, S. Jalal,B.L. Riggs,P.Roche,T.C.SpelsbergTissue,celltype,andbreastcancerstage-specific expression of a TGF-? inducible early transcription factorgene
  7. Allred DC. Ductal carcinoma in situ: terminology, classification, andnatural J Natl Cancer InstMonogr. 2010.
  8. W. ELSTON* and I.O. ELLISpathological prognostic factors in breastcancer. I. The value of histological grade in breast cancer: experience froma largestudywithlong-termfollow-up.HistopathologyVolume19,Issue5,pages 403–410, November1991
  9. K McPherson, C M Steel, and J M Dixon Breast cancer—epidemiology,risk factors, and genetics BMJ. 2000 Sep 9; 321(7261):624–
  10. American Cancer Detailed Guide: Breast Cancer. 2014. Accessedat http://www.cancer.org/Cancer/BreastCancer/DetailedGuide/indexon November 13,2014
  11. World Cancer Research Fund, American Institute for Cancer Research,Food Nutrition,PhysicalActivityandthePreventionofCancer:AGlobalPerspective
  12. Margaret L. McNeely, Kristin L. Campbell, Brian H. Rowe, Terry Klassen, JohnR.Mackey,KerryS.CourneyaEffectsofexerciseonbreastcancerpatients and survivors: a systematic review and meta-analysis CMAJ July4,2006 vol. 175 no. 1 doi:10.1503/cmaj.051073
  13. Akin, S., Can, G., Aydiner, , Ozdilli, K., and Durna, Z. (2010). Quality oflife, symptomexperienceanddistressoflungcancerpatientsundergoingchemotherapy. Eur. J. Oncol. Nurs. 14, 400–409.doi: 10.1016/j.ejon.2010.01.003
  14. Jain K.K. Nanotechnology: applications, market and companies, JainPharma
  15. Biotech Publications.2005.
  16. TorchilinP. Targeted pharmaceutical nanocarriers for cancer therapyand imaging. AAPS. 2007;9:128-147.
  17. Ajayan,OttoZ.Zhou.NanotubesofferApplicationsofCarbon Nanotubes. Applied Physics Volume 80, 2001, pp391-425
  18. NagavarmaV.N., HementK.S.Y., AyazA., VasudhaL.S, ShivakumarH.G. Differenttechniquesforpreparationofpolymeric nanoparticles–Areview. Asian J. of Pharm. and Clinical Research. 2012; 5, l3:17-23.
  19. Flahaut, E.; Bacsa, Revathi; Peigney, Alain; Laurent, Christophe(2003). "Gram-Scale CCVD Synthesis of Double-Walled CarbonNanotubes".
  20. BegS,RizwanM,SheikhAM,HasnainMS,Anwer K,KohliK:Advancement incarbonnanotubes:basics,biomedicalapplications and JPharmPharmacol, 2011, 63,141–163
  21. HouY1,Effectoftetrandrinecombinedwithepirubicinonthegrowthofhuman breast carcinoma multidrug resistance cell line. Yakugaku2008Apr;128(4):663-6.
  22. Brunbilla C, Ross A,BonfonteV, et al: Phase II study of doxorubicinvs epirubicin in advanced breast cancer.CancerTreat Rep 70:261-266,1986.
  23. http://www.rxlist.com/ellence-drug.htm
  24. Ismo Jantunen, VesaV. Kataja, TimoT. Muhonen, TapaniParviainen, Effects of granisetron with doxorubicin or epirubicin on ECGintervalsCancerChemotherapy and Pharmacology March 1996, Volume 37,Issue 5, pp502-504
  25. Lunardi1,Influenceoftrastuzumabonepirubicinpharmacokineticsinmetastatic breast cancer patientsOxfordJournalsMedicine&HealthAnnalsof OncologyVolume14, Issue 8Pp.1222-1226.
  26. Lisa Schulmeister. Extravasation Management. Seminars in OncologyNursing Volume 23, Issue 3, August 2007, Pages184–190
  27. http://seer.cancer.gov/statfacts/html/breast.html
  28. AhmedinJemal, Elizabeth Ward and Michael J Thun Recent trends inbreast cancer incidence rates by age and tumor characteristics among U.S.women. Breast Cancer Research 2007,9:R28
  29. ShahbaziR, HighBodyMassIndexandYoungAgeArenotAssociatedwith Post-Mastectomy Pain Syndrome in Breast Cancer Survivors: ACase-Control Study , Iran J Cancer 2015Jan-Feb;8(1):29-35.
  30. Croft L , Marital status and optimism score among breast cancer survivors, Support Care 2014 Nov;22(11):3027-34. doi:10.1007/s00520-014- 2308-y. Epub 2014 Jun8.
  31. Stacy Simon , Study Links Walking to Lower Breast Cancer Risk ,America
  32. cancer society article , October 4, 2013
  33. Azim HA , RANK-ligand (RANKL) expression in young breast cancerpatients andduringpregnancy, BreastCancerRes.2015Feb21;17(1):24.doi:10.1186/s13058-015-0538-7.
  34. Eur J Cancer Prev , Breast cancer and ages at first marriage and first birth:a new hypothesis , 2014Jan;23(1):53-7.
  35. William Dupont, Ph.D., and David L. Page, M.D , Risk Factors forBreast Cancer in Women with Proliferative BreastDisease
  36. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition,PhysicalActivity,andthePreventionofCancer:AGlobalPerspective. Washington, DC: American Institute for Cancer Research;2007.
  37. P.Cleary1,M.E.Grossmann1andA.Ray.EffectofObesityonBreastCancer Development. Veterinary Pathology March 2010 vol. 47 no. 2202-213
  38. Smith RA, Saslow D, Sawyer KA, et al. American CancerSociety guidelines for breast cancer screening: update 2003. CA Cancer JClin. May-Jun2003;53(3):141-69
  39. Prentice RL1 , Postmenopausal hormone therapy and the risks ofcoronary heartdisease,breastcancer,andstroke,SeminReprodMed.2014Nov;32(6):419-25. doi: 10.1055/s-0034-1384624. Epub 2014 Oct16.
  40. Kelsey JL, Gammon MD, John EM. Reproductive factors andbreast cancer. Epidemiol Rev.1993;15(1):36-47.
  41. Collaborative Group on Hormonal Factors in Breast Menarche, menopause, and breast cancer risk: individual participantmeta-analysis, including 118 964 women with breast cancer from 117epidemiological studies. Lancet Oncol. Nov2012;13(11):1141-51.
  42. SemiglazovVF, Moiseenko VM, Manikhas AG, et al. Interim results ofa prospectiverandomizedstudyofself-examinationforearlydetectionofbreast cancer. VoprOnkol.1999;45(3):265-71.
  43. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plusadjuvant chemotherapy for operable HER2-positive breast cancer. N Engl JMed. Oct 202005;353(16):1673-84.
  44. Chen BJ1, Small molecules targeting c-Myc oncogene: promisinganti- cancertherapeutics,IntJBiolSci.2014Sep13;10(10):1084-96.doi:10.7150/ijbs.10190. eCollection2014.
  45. Annalsofoncology,Acceleratedversusstandardcyclophosphamide,epirubicinand 5-fluorouracilorcyclophosphamide,methotrexateand5-fluorouracil: a randomized phase III trial in locally advanced breastcancer
  46. Baldini, G. Gardin and others,2002
  47. (StefanGlück,MD,PhDTheExpandingRoleofEpirubicinintheTreatment of Breast Cancer Cancer Control March/April 2002, 9,No.2 Supplement)
  48. David Sarid , Neoadjuvant Treatment with Paclitaxel and Epirubicinin Invasive Breast Cancer , Clin Drug Investig.2006;26(12):691-701.
  49. GennariA,SalvadoriB,DonatiS,etal:Cardiotoxicityofepirubicin/paclitaxel-containing regimens: Role of cardiac risk factors.J ClinOncol 17:3596-3602,1999.
  50. Pierfranco Conte , New Combinations With Epirubicin in AdvancedBreast Cancer , Oncology jurnal app , 24-27, 2001.
  51. D. Jones,A pilot study of quinidine and epirubicin in the treatmentof advanced breast cancer , Br J Cancer. 1990 Jul; 62(1):133–135.
  52. Ann S. Knoop, Retrospective Analysis of Topoisomerase IIaAmplifications andDeletionsAsPredictiveMarkersinPrimaryBreastCancerPatientsRandomly Assigned to Cyclophosphamide, Methotrexate, andFluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish BreastCancer Cooperative Group , American Society of ClinicalOncology.

[Jaamal Khlood, Aljoaid Linah, Alasmary Manal and Basmah Alazwari. (2017); ROLE OF NANOTECHNOLOGY IN EPIRUBICIN FOR BREAST CANCER THERAPY IN TAIF CITY Int. J. of Adv. Res. 5 (Feb). 981-1001] (ISSN 2320-5407). www.journalijar.com

Khlood Jaamal

DOI:

Article DOI: 10.21474/IJAR01/3244      
DOI URL: http://dx.doi.org/10.21474/IJAR01/3244

Download Full Paper

Download PDF No. of Downloads: 10 | No. of Views: 63